PPP2R3C Antibody

What is PPP2R3C and why is it significant for research?

PPP2R3C (Protein Phosphatase 2 Regulatory Subunit B'' Subunit Gamma) is a regulatory subunit of the PP2A phosphatase complex. It is encoded by the PPP2R3C gene located on chromosome 14q13.2 and consists of 13 exons encoding a 453-amino acid protein . Recent research has identified PPP2R3C as a distal centriole protein that functions as a key component in centrosomal phospho-regulation .

The significance of PPP2R3C in research stems from its critical roles in:

• Counteracting MAP3K1 kinase activity in centrosomal regulation

• Regulating the phosphorylation status of Sox9 protein

• Contributing to B-cell survival and immune function

• Playing a role in gonadal development, with mutations linked to syndromic 46, XY gonadal dysgenesis

This protein is particularly important for understanding centrosome function, microtubule organization, cell signaling, and specific developmental disorders.

What applications are PPP2R3C antibodies suitable for?

Based on validated testing, PPP2R3C antibodies have been successfully employed in several key research applications:

For optimal results, it's recommended to:

• Perform antigen retrieval with TE buffer pH 9.0 for IHC applications (alternatively, citrate buffer pH 6.0 can be used)

• Titrate the antibody concentration in each specific experimental system

• Validate reactivity in your specific sample type, as antibody performance can be sample-dependent

How should researchers select the appropriate PPP2R3C antibody for their experimental needs?

When selecting a PPP2R3C antibody, researchers should consider several critical factors:

• Target specificity: Confirm the antibody specifically recognizes PPP2R3C (not cross-reactive with other PP2A regulatory subunits)

• Species reactivity: Verify reactivity with your experimental model (common PPP2R3C antibodies show reactivity with human, mouse, and rat samples)

• Clonality: Determine whether polyclonal (broader epitope recognition) or monoclonal (single epitope specificity) is more appropriate for your application

• Host species: Consider potential cross-reactivity issues within your experimental system (rabbit-hosted antibodies are common for PPP2R3C)

• Validated applications: Ensure the antibody has been validated for your specific application (WB, IHC, ELISA)

• Isoform detection: Note that PPP2R3C has two isoforms produced by alternative splicing (53 kDa and 40 kDa)

Researchers should review validation data and literature citations before selecting an antibody to ensure compatibility with their experimental design.

How does PPP2R3C function within the centrosomal phospho-regulatory network?

Recent functional genomic analyses have revealed that PPP2R3C functions as part of a sophisticated centrosomal phospho-regulatory module:

PPP2R3C has been identified as a distal centriole protein that functions as a partner of centriolar proteins CEP350 and FOP. Its principal function appears to be counteracting the kinase activity of MAP3K1 within the centrosomal regulatory network .

This counterbalancing relationship is evidenced by several key experimental findings:

• MAP3K1 knockout suppresses growth defects caused by PPP2R3C inactivation

• MAP3K1 and PPP2R3C demonstrate opposing effects on both basal and microtubule stress-induced JNK signaling

• Acute overexpression of MAP3K1 severely inhibits centrosome function and triggers rapid centriole disintegration

This phospho-regulatory balance appears critical for normal centrosome function and cellular development. Disruptions to this balance through either inactivating PPP2R3C mutations or activating MAP3K1 mutations can lead to congenital syndromes characterized by gonadal dysgenesis .

For researchers studying centrosomal regulation, these findings highlight the importance of considering PPP2R3C within this broader regulatory network rather than in isolation.

What methodological approaches can be used to investigate PPP2R3C localization and protein interactions?

Investigating PPP2R3C localization and protein interactions requires sophisticated methodological approaches:

For subcellular localization studies:

• Immunofluorescence microscopy: Using validated PPP2R3C antibodies in combination with centrosomal markers (e.g., CEP350, FOP) to visualize co-localization at distal centrioles

• Super-resolution microscopy: For precise spatial localization within centrosomal structures

• Cell fractionation: To biochemically validate centrosomal enrichment

For protein interaction studies:

• Co-immunoprecipitation (Co-IP): To detect native PPP2R3C interactions with partners like CEP350 and FOP

• Proximity labeling approaches: Such as BioID or APEX to identify proximal proteins in living cells

• Yeast two-hybrid screening: To identify direct binding partners

• Pull-down assays: Using recombinant PPP2R3C to validate specific interactions

For functional interaction studies:

• Gene knockout/knockdown approaches: As demonstrated in MAP3K1 knockout experiments that showed suppression of PPP2R3C inactivation effects

• Phosphorylation assays: To measure changes in substrate phosphorylation (e.g., Sox9) when PPP2R3C activity is modulated

• JNK signaling assays: To assess opposing effects of PPP2R3C and MAP3K1 on this pathway

These methodological approaches should be combined for comprehensive characterization of PPP2R3C's centrosomal functions and regulatory relationships.

How can researchers effectively investigate the role of PPP2R3C in disease models?

Based on recent findings linking PPP2R3C mutations to syndromic disorders, researchers can employ several approaches to investigate its role in disease models:

Genetic approaches:

• CRISPR/Cas9 genome editing: To introduce patient-specific mutations (e.g., p.F229del, p.G417E) into cellular or animal models

• Patient-derived iPSCs: To study disease mechanisms in relevant cell types differentiated from patient cells

• Conditional knockout models: Similar to PPP2R3C-/- mice with conditional targeting in CD19+ B cells that showed deficits in B-cell survival

Cellular phenotyping:

• Centrosome integrity assays: To assess centriole stability and function

• Lymphocyte subset analysis: As patients show decreased CD19+ B cells (1.6%, normal range: 8.5%–14.5%) and CD4+ T cells (21.5%, normal range: 30.0-46.0%)

• Apoptosis assays: To investigate JNK-mediated apoptosis signals that PPP2R3C normally regulates

Developmental studies:

• Gonadal development models: To investigate the mechanisms leading to 46, XY gonadal dysgenesis

• Sox9 phosphorylation analysis: As PPP2R3C regulates the phosphorylation status of this developmentally critical protein

Clinical correlation studies:

• Genotype-phenotype mapping: Comparing different PPP2R3C variants with specific phenotypic manifestations

• Multi-system assessment: Including facial features, musculoskeletal abnormalities, immune function, and gonadal development

These approaches can help elucidate how PPP2R3C dysfunction contributes to the constellation of clinical features observed in patients with syndromic 46, XY gonadal dysgenesis and potentially other disorders.

What are the optimal storage and handling conditions for PPP2R3C antibodies?

Proper storage and handling of PPP2R3C antibodies is critical for maintaining their performance and specificity:

When handling PPP2R3C antibodies during experiments:

• Allow antibody to equilibrate to room temperature before opening

• Briefly centrifuge vials before opening to collect liquid at the bottom

• Use sterile techniques to prevent contamination

• Return to -20°C storage promptly after use

• Follow recommended dilution ranges specific to your application (WB: 1:500-1:1000; IHC: 1:20-1:200)

These storage and handling procedures will help maintain antibody quality and experimental reproducibility.

What control samples should be included when using PPP2R3C antibodies in experimental work?

Rigorous experimental design with appropriate controls is essential when working with PPP2R3C antibodies:

Positive controls:

• Tissue samples: Mouse and rat brain tissues have been validated for WB applications; human brain tissue for IHC applications

• Cell lines: Cell lines with known PPP2R3C expression (researcher should validate expression levels)

• Recombinant protein: Purified PPP2R3C protein as a size and specificity reference

Negative controls:

• Knockdown/knockout samples: Cells with CRISPR or siRNA-mediated PPP2R3C depletion

• Secondary antibody-only controls: To assess background signal

• Isotype controls: Non-specific rabbit IgG at matching concentration to assess non-specific binding

• Blocking peptide controls: Pre-incubation of antibody with immunizing peptide to confirm specificity

Experimental validation controls:

• Molecular weight verification: PPP2R3C has two isoforms (53 kDa and 40 kDa)

• Cross-reactivity assessment: Testing in multiple species if working across species boundaries

• Method-specific controls:

  • For WB: Loading controls (β-actin, GAPDH)

  • For IHC: Tissue-specific controls and counterstains

  • For Co-IP: Input controls and IgG controls

Implementing these controls will enhance data quality and interpretability when working with PPP2R3C antibodies.

How can researchers troubleshoot common issues when working with PPP2R3C antibodies?

When working with PPP2R3C antibodies, researchers may encounter several common challenges. Here are methodological approaches to troubleshoot these issues:

Issue: Weak or no signal in Western blot

• Solution 1: Optimize protein extraction using buffers containing phosphatase inhibitors (critical for phosphatase subunits)

• Solution 2: Increase antibody concentration (try 1:250 if 1:500 is insufficient)

• Solution 3: Extend primary antibody incubation time (overnight at 4°C)

• Solution 4: Use enhanced chemiluminescence detection systems with longer exposure times

• Solution 5: Verify sample preparation (PPP2R3C may require specific extraction methods for membrane-associated proteins)

Issue: Multiple bands or unexpected molecular weight in Western blot

• Solution 1: Remember PPP2R3C has two isoforms (53 kDa and 40 kDa)

• Solution 2: Optimize SDS-PAGE conditions (8-10% gels typically work well)

• Solution 3: Add protease inhibitors to prevent degradation

• Solution 4: Validate with recombinant protein control

Issue: High background in IHC

• Solution 1: Optimize blocking (try 5% BSA or 10% normal serum from secondary antibody host species)

• Solution 2: Increase washing steps and duration

• Solution 3: Dilute antibody further (1:50-1:200 range)

• Solution 4: Optimize antigen retrieval (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

• Solution 5: Use signal amplification systems for weak signals while maintaining specificity

Issue: Inconsistent results between experiments

• Solution 1: Standardize all protocol parameters (incubation times, temperatures, buffer compositions)

• Solution 2: Use consistent positive and negative controls

• Solution 3: Prepare fresh working dilutions for each experiment

• Solution 4: Document lot numbers and validate each new antibody lot

These troubleshooting approaches can help researchers achieve consistent and reliable results when working with PPP2R3C antibodies.

How should researchers interpret PPP2R3C expression patterns in different cellular contexts?

Interpreting PPP2R3C expression patterns requires careful consideration of cellular context and methodological approach:

Subcellular localization interpretation:
PPP2R3C has been identified as a distal centriole protein , but its distribution may vary depending on cell cycle stage, cell type, and experimental conditions. Researchers should:

• Compare PPP2R3C localization with established centrosomal markers (CEP350, FOP)

• Assess potential relocalization during mitosis or under stress conditions

• Consider that syndromic PPP2R3C variants can be defective in centriolar localization

Tissue expression interpretation:
PPP2R3C shows differential expression across tissues, with notable expression in:

• Brain tissue (validated in human, mouse, and rat samples)

• Immune cells (particularly B lymphocytes)

• Gonadal tissues (relevant to its role in gonadal development)

Expression in disease contexts:
Changes in PPP2R3C expression or localization may indicate:

• Disrupted centrosomal regulation

• Altered phosphorylation balance affecting Sox9 or other substrates

• Potential compensatory mechanisms in response to MAP3K1 activity changes

• Relevance to cellular phenotypes in gonadal dysgenesis

When interpreting experimental results, researchers should consider both quantitative changes in expression level and qualitative changes in localization pattern, as both can indicate altered PPP2R3C function.

What is the significance of PPP2R3C-MAP3K1 balance in experimental design and data interpretation?

The recently discovered PPP2R3C-MAP3K1 phospho-regulatory relationship has significant implications for experimental design and data interpretation:

The critical balance between PPP2R3C (phosphatase activity) and MAP3K1 (kinase activity) creates a dynamic phosphorylation equilibrium that affects:

• Centrosome function and integrity

• JNK signaling pathway activity

• Cellular growth and development

• Gonadal development

Experimental design considerations:

• Dual pathway modulation: When modulating PPP2R3C activity, researchers should consider monitoring MAP3K1 activity simultaneously

• Compensatory mechanisms: Knockout or overexpression of one component may trigger compensatory changes in the other

• Substrate monitoring: Identify and monitor phosphorylation status of downstream substrates (e.g., JNK pathway components)

• Rescue experiments: Test if MAP3K1 knockout can suppress phenotypes caused by PPP2R3C inactivation

Data interpretation guidance:

• Phenotypic similarities: Both inactivating PPP2R3C mutations and activating MAP3K1 mutations cause syndromes with gonadal dysgenesis, suggesting a common mechanistic pathway

• Opposing effects: PPP2R3C and MAP3K1 have opposing effects on both basal and microtubule stress-induced JNK signaling

• Threshold effects: Consider that biological outcomes may depend on reaching critical thresholds of phosphorylation rather than showing linear relationships

• Centrosomal integrity: Acute overexpression of MAP3K1 severely inhibits centrosome function and triggers rapid centriole disintegration

Understanding this balance is crucial for correctly interpreting experimental outcomes and designing interventions that might restore normal phosphorylation equilibrium in disease states.

How can researchers integrate PPP2R3C findings with broader scientific literature on centrosomal regulation?

To effectively integrate PPP2R3C research with the broader scientific understanding of centrosomal regulation, researchers should:

Connect with established centrosomal regulatory pathways:

• Examine how PPP2R3C-MAP3K1 interaction relates to known centrosomal kinases (PLK1, Aurora A)

• Investigate potential cross-regulation with other phosphatases active at centrosomes

• Consider cell cycle-specific regulation of the PPP2R3C-MAP3K1 module

• Explore connections to microtubule nucleation and organization pathways

Link to developmental biology:

• Investigate how PPP2R3C regulation of Sox9 phosphorylation affects gonadal development

• Examine potential roles in other developmental processes where centrosome function is critical

• Consider PPP2R3C's role in cellular differentiation, especially in B cell development

Apply systems biology approaches:

• Use protein-protein interaction networks to map PPP2R3C's position in the centrosomal interactome

• Perform phosphoproteomics after PPP2R3C modulation to identify substrates

• Develop computational models of the PPP2R3C-MAP3K1 phosphorylation balance

• Integrate genetic and proteomic datasets to identify functional relationships

Translate to disease mechanisms:

• Compare syndromic features of PPP2R3C mutations with other centrosomal disorders

• Investigate potential roles in cancer, as PPP2R3C antibody shows reactivity in stomach cancer tissue

• Consider broader implications for disorders of sex development beyond 46, XY gonadal dysgenesis

• Examine potential connections to immune disorders given PPP2R3C's role in lymphocyte development

By placing PPP2R3C research within these broader contexts, researchers can contribute to a more comprehensive understanding of centrosomal regulation and its implications for development and disease.

What are the emerging research areas for PPP2R3C antibody applications?

Based on recent discoveries about PPP2R3C function, several promising research directions are emerging:

Developmental biology applications:

• Investigating PPP2R3C's role in gonadal development across different model organisms

• Tracking Sox9 phosphorylation status during critical developmental windows

• Exploring potential roles in other developmental contexts beyond gonadal development

Centrosomal dynamics:

• Using super-resolution microscopy with PPP2R3C antibodies to map precise centrosomal localization

• Developing live-cell imaging approaches using fluorescently tagged antibody fragments

• Investigating centrosomal changes during cell cycle progression and in disease states

Disease mechanism exploration:

• Applying PPP2R3C antibodies to histopathological studies of 46, XY gonadal dysgenesis

• Investigating potential roles in cancer biology, particularly in contexts of centrosomal amplification

• Exploring lymphocyte development disorders given PPP2R3C's role in immune cell function

Therapeutic target validation:

• Using antibodies as tools to validate PPP2R3C as a potential therapeutic target

• Developing approaches to modulate the PPP2R3C-MAP3K1 balance in disease states

• Screening for small molecules that could restore normal PPP2R3C function in mutant contexts

These emerging research areas highlight the growing importance of PPP2R3C in multiple biological contexts and the value of well-characterized antibodies for advancing our understanding of its functions.

How should researchers approach experimental design when studying novel PPP2R3C variants?

When designing experiments to study novel PPP2R3C variants (such as those identified in syndromic 46, XY gonadal dysgenesis), researchers should implement a comprehensive analytical approach:

Structural and functional prediction:

• Analyze conservation of affected amino acids across species (as done for F229 and G417)

• Perform in silico structural analysis to predict effects on protein folding and domain function

• Assess potential impacts on protein-protein interactions, particularly with centrosomal partners

Expression and localization studies:

• Generate expression constructs for wild-type and variant PPP2R3C

• Compare subcellular localization using immunofluorescence with validated antibodies

• Assess binding to known partners (CEP350, FOP) through co-immunoprecipitation

• Evaluate protein stability and turnover rates for variants

Functional assays:

• Measure phosphatase activity against known or predicted substrates

• Assess effects on MAP3K1-mediated phosphorylation events

• Evaluate JNK pathway signaling with and without microtubule stress

• Test centrosome integrity and function in variant-expressing cells

Cell-type specific analyses:

• Study effects in gonadal cell lineages relevant to dysgenesis phenotypes

• Assess lymphocyte development and function given immune phenotypes

• Compare effects across different cell types to identify tissue-specific vulnerabilities

In vivo modeling:

• Generate knock-in animal models of specific variants when feasible

• Compare with complete knockout models to distinguish loss-of-function from gain-of-function effects

• Assess developmental outcomes with particular attention to gonadal development